LivaNova PLC reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with net revenue reaching $1.39 billion, a 10.7% increase from $1.25 billion in 2024. The company's gross profit also rose to $939.9 million, up from $853.5 million the previous year. However, LivaNova recorded a net loss of $242.5 million, compared to a net income of $63.2 million in 2024, primarily due to a $365.6 million expense related to environmental liabilities associated with the SNIA case. The operating income improved to $199.4 million from $129.1 million in 2024, reflecting operational efficiencies despite the overall loss.
The company experienced notable growth in its Cardiopulmonary and Neuromodulation segments. Cardiopulmonary revenue increased by 14.9% to $785.4 million, driven by strong demand for consumables and the Essenz Perfusion System. Neuromodulation revenue grew by 7.0% to $592.8 million, with increases across all regions. The segment income for Cardiopulmonary rose to $108.3 million, while Neuromodulation's segment income reached $215.5 million, indicating effective cost management and revenue generation strategies.
Strategically, LivaNova has focused on enhancing its core segments through product development and clinical studies. The company has made significant investments in research and development, amounting to $185.8 million, which represents 13.4% of its net revenue. This investment includes advancements in the aura6000 System for treating obstructive sleep apnea and ongoing clinical trials for its VNS Therapy System. Additionally, LivaNova has been actively managing its debt, successfully repaying $280.9 million in long-term debt during the year, which has improved its financial leverage.
Operationally, LivaNova reported a workforce of approximately 3,300 employees across 34 countries, reflecting its global reach. The company has maintained a strong presence in the U.S., Europe, and other regions, with net revenue contributions of 53%, 19%, and 28%, respectively. The company’s commitment to innovation and market expansion is evident in its ongoing clinical studies and product launches, which are expected to drive future growth.
Looking ahead, LivaNova anticipates continued growth in its core segments, supported by its strategic initiatives and product development efforts. However, the company remains cautious about potential challenges, including regulatory changes, market competition, and the impact of global economic conditions on its operations. The management's outlook emphasizes a focus on operational efficiency and innovation to navigate these challenges and capitalize on emerging opportunities in the medical technology sector.
About LivaNova PLC
LivaNova PLC is a global medical technology company specializing in devices for neurological and cardiac conditions. Its core segments include Cardiopulmonary products like heart-lung machines and oxygenators, and Neuromodulation therapies such as vagus nerve stimulation for epilepsy and depression. The company develops innovative, regulatory-compliant solutions for hospitals worldwide, emphasizing quality, clinical evidence, and cost-effective delivery to improve patient outcomes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.